Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Brentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.

Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.

Sacituzumab (hRS7) is an antibody inhibitor and a humanized monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2), serving as a component of the antibody-drug conjugate sacituzumab govitecan, used for research and treatment of TROP2-high-expressing tumors such as triple-negative breast cancer.

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

Milatuzumab (MEDI-115) is a humanized monoclonal antibody against CD74. Milatuzumab promotes the production of free radical oxygen and the loss of mitochondrial membrane potential, reduces CD20/CD74 aggregates and cell adhesion, and induces cell death.

Datopotamab (CDP7657) is a TROP2-targeting antibody that is a naked antibody to Datopotamab deruxtecan and can be used to synthesize active antibody conjugators (Datopotamab deruxtecan). Datopotamab is being investigated for use in triple-negative breast cancer and non-small cell lung cancer.

Mirvetuximab (M9346A) is a novel folate receptor α (FRα) monoclonal antibody targeting anti-FOLR1 (folate receptor 1). Mirvetuximab soravtansine is often conjugated with platinum compounds or other compounds to form antibody-drug conjugates for the treatment of ovarian cancer and other FRα-positive cancers.

Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targeting tissue factor (TF), utilized in antibody-conjugating drugs for cancer research.

Anetumab is a novel fully human anti-mesothelin IgG1 antibody that is a naked antibody to Anetumab ravtansine.Anetumab can be used to synthesize the antibody-activated molecule coupling, Anetumab ravtansine.Anetumab can be used to study the treatment of metastatic pleural mesothelioma.

Gemtuzumab(CMA-676) is a monoclonal antibody directed against the CD33 antigen and consists of a recombinant humanized IgG4 antibody.Gemtuzumab can be used to synthesize Gemtuzumab ozogamicin, an antibody coupled compound (ADC) Gemtuzumab is used in the study of acute myeloid leukemia.

Enfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in conjunction with platinum compounds to study uroepithelial cancers.

Zilovertamab (UC-961) is a humanized anti-ROR1 monoclonal antibody that cuts off the WNT5A-induced ROR1 signaling pathway and shows anti-proliferative activity in ovarian and endometrial cancer cells. It can be used to study lymphatic cancer.

Samrotamab (PR-1498487) is a humanized anti-LRRC15 antibody that can be used to synthesize the ADC compound (Samrotamab vedotin).

Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3) and is utilized to synthesize antibody-active molecule conjugates (ADCs). It exhibits anticancer activity and is used in the treatment of small cell lung cancer (SCLC).

Aprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize antibody-drug conjugates.

Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody that is a naked antibody to the ADC compound Losatuxizumab vedotin, with potential anti-tumor activity for the study of advanced malignant solid tumors.

Belantamab (GSK2857914) is a humanized IgG1 monoclonal antibody against BCMA (TNFRSF17). Belantamab is a naked antibody to Belantamab mafodotin and can be used to synthesize antibody-active molecule conjugates (Belantamab mafodotin).

Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized anti-CD33 monoclonal antibody that can be used for the synthesis of the ADC compound Vadastuximab talirine and for the study of acute myeloid leukemia (AML).

Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritumab promotes apoptosis and inhibits proliferation in non-small cell lung cancer.

Naratuximab (Anti-TSPAN26/CD37 Reference Antibody) is a humanized monoclonal antibody against CD37 that can be used to synthesize the ADC compound Naratuximab emtansine.

Codrituzumab (GC3) is a humanized antibody against the glypican-3 hepatocellular carcinoma protein that can be used in combination with sorafenib to study incurable advanced hepatocellular carcinoma (HCC).